Grade | Description | Benefit vs risks | Quality of studies | Implications |
---|---|---|---|---|
1A | Strong recommendation, high-quality evidence | Benefits clearly outweigh risks and burdens or vice versa | RCTs without important limitations or overwhelming evidence from observational studies | Strong recommendation; can apply to most patients in most circumstances without reservation |
1B | Strong recommendation, moderate-quality evidence | Benefits clearly outweigh risks and burdens or vice versa | RCTs with important limitations or exceptionally strong evidence from observational studies | Strong recommendation; can apply to most patients in most circumstances without reservation |
1C | Strong recommendation, low or very low-quality evidence | Benefits clearly outweigh risks and burdens or vice versa | Observational studies or case series | Strong recommendation but may change when higher-quality evidence becomes available |
2A | Weak recommendation, high-quality evidence | Benefits closely balanced with risks and burdens | RCTs without important limitations or overwhelming evidence from observational studies | Weak recommendation; best action may differ depending on circumstances or patients’ or societal values |
2B | Weak recommendation, moderate-quality evidence | Benefits closely balanced with risks and burdens | RCTs with important limitations or exceptionally strong evidence from observational studies | Weak recommendation; best action may differ depending on circumstances or patients’ or societal values |
2C | Weak recommendation, low or very low-quality evidence | Uncertainty in the estimates of benefits, risks, and burdens; benefits, risks, and burdens may be closely balanced | Observational studies or case series | Very weak recommendation; other alternatives may be equally reasonable |